Hammer et al. 1 examined 2817 subjects, including 1325 healthy subjects and patients with schizophrenia (1081), Parkinson disease (263) and affective disorders (148) for the presence of several immunoglobulin subtypes of antibodies against the NR1 subunit of the NMDA receptor (NMDAR). In this large-scale screening, they found that 10.5% of all subjects were seropositive. The authors conclude that schizophrenic individuals with a past or present history of blood-brain barrier (BBB) disturbance are more likely to have more pronounced neurological symptoms upon NMDAR antibody seropositivity. However, there is no data supporting this conclusion in any of the sections of the manuscript:
(1) The authors' conclusion was based on retrospective review of clinical information for possible neurotrauma at birth or thereafter in the patients and controls. Even assuming that there was neurotrauma (which in fact is not clearly demonstrated), the authors do not provide any evidence that it altered the integrity of the BBB. (2) In the experiments with cultured neurons the authors claim that decreased NMDAR immunostaining was visible with confocal microscopy after incubation with patients' antibodies for 20 min, 'subsequently placing the cells in pre-warmed growth medium for 15 min to allow internalization.' However, other than a graph, there is no data showing confocal microscopy pictures of the density of cell surface/synaptic NMDAR clusters before and after incubation with patients' antibodies. The findings are hard to explain given that studies by other investigators on antibody-mediated NMDAR internalization using patient samples with very high titer antibodies (for example, those with anti-NMDAR encephalitis) found no detectable internalization using confocal microscopy until~4 h after neuronal incubation, reaching a plateau at~24 h. 2, 3 (3) In contrast to the authors' suggestion, the mouse experiments do not provide supporting evidence to their interpretation of the patients' findings (point 1). For this, in the minimum, the authors should demonstrate that the systemic injection of patients' immunoglobulin G (IgG) reaches the brain of mice, binds to NMDAR and alters receptor levels and function.
In a clinical series by Steiner et al., 4 including 459 subjects (121 with schizophrenia, 70 major depression, 38 borderline personality disorder (BLPD) and 230 controls), none had IgG NR1 subtype antibodies (two positive cases had anti-NMDAR encephalitis)-a finding closely resembling the data of Hammer et al. 1 (18/2817, 13 patients, 5 controls; 0.6%). However, Steiner et al. 4 found that 9.9% patients with schizophrenia, 2.8% major depression, 0% BLPD and 0.4% controls had IgA or IgM antibodies, or IgG antibodies against NR1/NR2. The different incidence of NMDAR antibodies in healthy subjects of both series (137/1325 (10.8%) versus 1/230 (0.4%)) is surprising.
Overall, these findings cast doubt on the interpretation that Hammer et al. 1 made on their results, and show the difficulty that these authors and Steiner et al. 4 encountered in the interpretation of antibody testing (using only serum and a cell-based assay), a problem we recently reported. 5 In our opinion, the study of Hammer et al.
1 merely shows that NR1 IgG antibodies are extremely uncommon in patients with schizophrenia, and IgA or IgM antibodies are frequent among healthy individuals, lacking specificity.
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Dr Dalmau holds a patent application for the use of NMDA receptor as antibody test, and has received a research grant for Euroimmun. Dr Titulaer received a travel grant for lecturing in India from Sun Pharma, India. 4 Any further comments on this topic are thus outdated. More importantly, Titulaer and Dalmau 1 question the validity of a widely used cell biological technique for measuring the internalization of membrane proteins from the cell surface. In fact, endocytosis duration determines the endocytic compartment, with early endosome appearing after 5-10 min, already recycling endosomes at 30 min, and late endosomes at 30-60 min. Thus, after ⩾ 30 min one would expect recycling to occur. 5, 6 Titulaer and Dalmau 1 cite a paper that does not investigate internalization. 7 It shows in cultured neurons consequences on surface NMDAR1 expression of an exposure for 1-7 days to human anti-NMDAR1 immunoglobulin (Ig)G. Although this time frame is certainly long enough to include endocytosis, days of serum contact allow for many secondary adaptations, including well-known toxicity effects that have not been distinguished by the authors from the internalization of NR1. In contrast, we did analyze endocytosis and found exactly what was predicted, notably for all investigated Ig subclasses, IgG, IgA and IgM. We are adding representative confocal images, before and after permeabilisation of neurons, reflecting our experimental conditions (Supplementary Figure S1) .
OPEN
We also provided experimental evidence that circulating NMDAR-AB induced behavioral abnormalities only in ApoE − / − mice with their known leaky blood-brain barrier (BBB), 8 but not in respective controls. It was our specific intention to investigate behavior in this mouse model as a translational readout of psychiatric symptoms. Moreover, in a retrospective, hypothesisdriven analysis, we found more pronounced neurological symptoms in well-characterized NMDAR-AB seropositive patients with likely (but not proven) compromised BBB due to birth complications or past neurotrauma, 2 in line with earlier studies (for review see ref. 9). To further support the hypothesis of a permeable BBB as prerequisite for circulating NMDAR-AB to influence brain function, we now provide additional data.
Here, we determined the apolipoprotein E (APOE) carrier status in a total of 2492 individuals tested twice independently for serum NMDAR-AB.
2,10 DNA was isolated from blood using the JETQUICK Blood and Cell Culture Kit (Genomed, Loehe, Germany). The two single-nucleotide polymorphisms (SNPs) rs7412 and rs429358 were genotyped using the KASP genotyping system (LGC Genomics, Berlin, Germany). These two SNPs allow determination of the APOE allele status (APOE2, APOE3 and APOE4). Failed samples (3.7%) were Sanger-sequenced using primers flanking both SNPs (forward: 5′-AACAACTGACCCCGGTGGCG-3′, reverse: 5′-TCCGGCTGCCCATCTCCTCC-3′). Group differences in categorical variables were assessed using binary logistic regression, including NMDAR-AB and APOE4 carrier status, and age as covariates. Pearson's χ 2 P-values are displayed in Table 1 . In case of No 5 in one cell, Fisher's exact test was employed.
APOE4 carrier frequency was not significantly different in neuropsychiatric disease groups compared with controls (24.3%) (Supplementary Table S1 ). The higher frequency in bipolar patients (33.3%) did not reach statistical significance. NMDAR-AB were present in 71 individuals with at least one APOE4 allele (2.8% of 2492 subjects). Whereas χ 2 statistics did not show significant deviations from the theoretical distribution in case of schizophrenia, bipolar disorder, unipolar depressive patients and health, an excess of schizoaffective patients carried both APOE4 and NMDAR-AB (P = 0.001, relative odds (OR) = 4.929) (Supplementary Table S2 ). Compared with controls, the interaction of APOE4 carrier status and NMDAR-AB seropositivity was significantly associated with schizoaffective disorder (P = 0.001, OR = 6.109), corrected for APOE4 and NMDAR-AB main effects, and age (Table 1) . Although the percentage of bipolar patients carrying both NMDAR-AB and APOE4 exceeded that of schizoaffective patients (6.7 vs 5.5%), there was no significant association, possibly owing to low statistical power (N = 60). No difference was found with respect to disease phenotypes, or age at prodrome or disease onset after correction for multiple testing (Supplementary Tables S3a and b) .
In summary, these novel results again highlight the importance of the BBB for NMDAR-AB-mediated pathology. APOE4 is associated with BBB leakage in mouse and man. 8, 11 Delusions of grandiosity and mania are common psychiatric symptoms in anti-NMDAR encephalitis. 12 Thus, NMDAR-AB may cause or boost these symptoms in neuropsychiatrically ill APOE4 carriers, which are then more likely diagnosed schizoaffective. Independent replication is necessary, but future studies investigating NMDAR-AB in neuropsychiatric disorders should consider factors determining BBB integrity.
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